Table 3.

Treatment-related adverse events occurring in at least 10% of patients and corresponding grade 3/4 events (safety analysis sets)

Low/Negative EGFR (N = 203)High EGFR (N = 182)
Any gradeGrade 3Grade 4Any gradeGrade 3Grade 4
Patients with any adverse event, n (%)197 (97)47 (23)4 (2)169 (93)44 (24)5 (3)
Adverse events, n (%)
    Acneiform dermatitis140 (69)12 (6)0125 (69)16 (9)0
    Pruritus139 (68)7 (3)095 (52)6 (3)0
    Erythema133 (66)11 (5)0111 (61)13 (7)0
    Rash59 (29)7 (3)042 (23)5 (3)0
    Exfoliative rash48 (24)5 (2)030 (16)4 (2)0
    Fatigue42 (21)3 (1)034 (19)4 (2)1 (1)
    Paronychia42 (21)1 (<1)032 (18)3 (2)0
    Skin fissures31 (15)0023 (13)1 (1)0
    Diarrhea30 (15)3 (1)023 (13)1 (1)0
    Nausea27 (13)3 (1)060 (33)7 (4)1 (1)
    Hypomagnesemia23 (11)6 (3)1 (<1)16 (9)3 (2)0

NOTE: The safety analysis sets included all patients who received at least one dose of panitumumab.